頁籤選單縮合
題名 | Durable Response to Lapatinib Plus Capecitabine in Trastuzumab--Resistant HER2 Over-expressing Metastatic Breast Cancer=Lapatinib與Capecitabine於具Trastuzumab抗性且表皮生長因子陽性的轉移性乳癌有長期療效 |
---|---|
作者 | 陳鵬宇; 劉美瑾; 陳啟明; 曹美華; 黃麟傑; 陳竹筠; | 書刊名 | 臺灣癌症醫學雜誌 |
卷期 | 27:3 2011.06[民100.06] |
頁次 | 頁123-132 |
分類號 | 416.226 |
關鍵詞 | 泰嘉錠; 第二型人類表皮生長因子受體過量表現; 賀癌平抗藥性; Lapatinib; HER2 overexpression; Trastuzumab resistenance; |
語文 | 英文(English) |
中文摘要 | 抗表皮生長因子藥物對於表皮生長因子陽性的轉移性乳癌病人而言,是一項非常重要的治療,它能有效改善表皮生長因子陽性的轉移性乳癌的預後。在此報告一位54歲女性在第一期乳癌的手術與抗荷爾蒙治療一年後,發現具有表皮生長因子接受器陽性的肝轉移,在接受傳統化療藥物與trastuzumab治療無效後,予以 lapatinib與capecitabine治療,有效控制長達兩年以上。在此我們討論分析第二線抗表皮生長因子藥物 (lapatinib) 的藥效與機轉。 |
英文摘要 | HER2-directed therapy has become an important agent in the treatment of metastatic breast cancer, and has altered the natural course of HER2- overexpressing breast cancer. We report a 54-year-old woman with initial stage breast cancer with subsequent metastasis to the liver, with positive ER and PR, and HER2 over-expression within one year of mastectomy and adjuvant hormone therapy. The patient showed a lengthy positive response, two years in duration,to lapatinib and capecitabine after resistance build-up to traditional chemotherapy and trastuzumab treatment. Here we discuss the effectiveness and mechanisms of the second line anti-HER2 treatment, lapatinib. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。